Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the blood pressure lowering effect and safety of
aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy
when given to metabolic syndrome patients with stage 2 systolic hypertension (mean sitting
systolic blood pressure [msSBP] ≥ 160 mm Hg and < 200 mm Hg).